Pheochromocytoma primary prevention
Pheochromocytoma Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Pheochromocytoma primary prevention On the Web |
American Roentgen Ray Society Images of Pheochromocytoma primary prevention |
Risk calculators and risk factors for Pheochromocytoma primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.
Overview
Biochemical screening for family members of MEN2 patients is mandatory.Genetic testing should be performed in first-degree relatives of a patient with proven germline RET mutation.
Primary Prevention
- According to the Endocrine Society, screening for familial pheochromocytoma is associated with many syndromes. Multiple endocrien neoplasia (MEN2) is one of them. Biochemical screening for family members of MEN2 patients is mandatory.
- Biochemical screening for pheochromocytoma in pediatric patients with VHL starting at 5 years of age with lifelong biochemical surveillance every year and the use of anatomic imaging when norepinephrine levels are elevated more than two times upper normal limits.[1]
- Plasma fractionated metanephrines as the best test in this case. Normal values are enough to stop any further tests but if elevated results, 24-hour urinary fractionated metanephrines should be done.
- Genetic testing should be performed in:[2]
- First-degree relatives of a patient with proven germline RET mutation
- Parents whose young children have MEN type2
- Patients with cutaneous lichen amyloidosis
- Families whose infants or young children have Hirschsprung disease (HD)